Connect with us
Boehringer Ingelheim Spain significantly increased its R&D&I investment to 62.7 million euros, up 36% from the previous year, representing 11.5% of net sales. Their human health...
Boehringer Ingelheim has developed this new obesity drug with Zealand Pharma. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1, which suppresses appetite and helps...
Boehringer Ingelheim reached a sales figure of €24.1 billion in 2022, which translates into a year-on-year rise of 10.5%. In 2022, the Spanish subsidiary registered an...
The new healthcare information and data environment that Europe intends to develop "will be the driving force behind healthcare research, the development of digital technologies and...
The operating revenues of Boehringer Ingelheim increased to $5.44 billion (€4.62 billion) in 2020, up from $4.45 billion (€3.78 billion) in 2019.The company invested $4.4 billion...